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Investigators in the redox biology field have long recognized the unique rolemitochondrial superoxide gener-
ation plays in physiological signaling and in dysregulated bioenergetic dysfunction. Pharmacological manip-
ulation has been challenging, and in this issue of Chemistry & Biology, Kelso and colleagues present the
synthesis and characterization of a novel mitochondrial-targeted SOD mimetic, MitoSOD.With an increasing need to attenuate the
pathological effects of reactive oxygen/
nitrogen species (ROS/RNS) on mito-
chondrial function, there has been a
concerted effort to develop bioenergetic
based therapeutics (Wallace et al.,
2010). Within the last decade, a class
of compounds, referred to as mitochon-
dria-targeted antioxidants, and most
notably mitoquinone, have gained wide-
spread attention and have been shown
to be effective in preventing or reversing
dysfunctional mitochondrial signaling
or damage in experimental models
of disease (Chacko et al., 2010, 2011;
Mitchell et al., 2011; Murphy, 2008). The
development of these compounds has
renewed interest in understanding the
oxidant network in mitochondria and its
regulation. The origin of this network is
superoxide, which is the primary free
radical generated during electron trans-
port. Superoxide can be transformed to
a spectrum of other reactive species and
can contribute to redox signaling to the
cytosol and within the mitochondrion.
Much of the evidence for the role of
mitochondrial superoxide in this redox
signaling network has been obtained
from studies in which the expression of
the endogenous superoxide dismutase
(MnSOD) has been either suppressed
or enhanced (Macmillan-Crow and Cru-
thirds, 2001). From these findings, it
is apparent that MnSOD is essential
for regulating superoxide, hydrogen per-
oxide, and peroxynitrite steady state
levels and signaling by each of these reac-
tive species (Brookes and Darley-Usmar,
2002). Inhibition of MnSOD activity
by ROS/RNS-dependent modifications
such as tyrosine nitration has been
shown to lead to excess oxidant gene-ration and cell death (Cruthirds et al.,
2003), whereas dephosphorylation of
MnSOD stimulates activity (Hopper
et al., 2006).
Clearly, the data with experimental
models of MnSOD suggest that phar-
macological supplementation could be
therapeutically beneficial in those cir-
cumstances where either expression is
inadequate or oxidative modification
decreases the levels of functional enzyme.
Although a robust literature has ex-
plored the therapeutic potential of SOD
mimetics, no compound has been devel-
oped with the specific goal of modulating
intra-mitochondrial superoxide levels.
In this issue of Chemistry and Biology,
Kelso et al. (2012) describe the develop-
ment of MitoSOD, the first attempt to
selectively modulate the mitochondrial
redox network through control of super-
oxide. The approach they have taken
builds upon the author’s previous ex-
perience in using the delocalized cation,
triphenylphosphonium (TPP+), to carry
a molecule of interest into the mitochon-
drion (Murphy, 2008). The compound
they have selected as cargo is M40403,
a well established macrocyclic SOD
mimetic that has been shown to have
anti-inflammatory effects in a number of
in vivo models (Salvemini et al., 2001).
The activity of the macrocyclic SOD
mimetic is highly susceptible to chemical
modification, as shown previously by the
authors (Maroz et al., 2008). In the first
series of experiments, they found that
incorporation of the TPP+ moiety does
not impact the intrinsic antioxidant acti-
vity of the parent compound. Importantly,
ascorbate, which is present in the mito-
chondrion at a high concentration, can
enhance superoxide dismutase activity.Chemistry & Biology 19, October 26, 2012 ªIn addition, the authors showed that
MitoSOD accumulated approximately
3,000-fold in energized mitochondria,
where it remained stable and metabolized
superoxide to hydrogen peroxide. Admin-
istration of the non-mitochondrial tar-
geted M40403 did not elicit the same
effects and further supports the require-
ment of targeting the SOD mimetic to
achieve effective concentrations of the
compound within the organelle. Stability
studies with MitoSOD showed that it
retained Mn2+ ion except under acidic
conditions where the half-life is only a
few minutes. Clearly, this would limit the
therapeutic potential to acute pathologies
where direct administration avoiding the
acidic conditions of the stomach is
possible.
Mitochondrial membrane potential is
required for mitochondria targeted com-
pounds to localize within the mito-
chondria, and MitoSOD is most likely
accumulated into the organelle as the
monocation. With isolated mitochondria,
it is not possible to assess the impact
of MitoSOD on cell signaling, but the
potential protective effects of excess
superoxide generation can be evaluated.
To achieve this, the authors exposed iso-
lated heart mitochondria to paraquat,
a compound that generates superoxide
through redox cycling. Within the mito-
chondrion, one of the most susceptible
proteins to superoxide toxicity is the
FeS containing protein aconitase. The
rapid and progressive inhibition of aconi-
tase by paraquat was significantly at-
tenuated by MitoSOD, but not M40403,
consistent with the augmentation of
SOD activity within the organelle and the
requirement for accumulation into the
mitochondrion.2012 Elsevier Ltd All rights reserved 1217
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PreviewsIn summary, the development of
MitoSOD by Kelso et al. (2012) is a
notable advancement in the field be-
cause it introduces a new and previously
neglected chapter in the development
of SOD mimetics. This is timely since it
is quite clear that controlled production
of superoxide both in the cytosol, by
NADPH oxidases, and in the mitochon-
drion play an important role in the normal
physiology and pathology of disease.
We look forward to the application of
this exciting new technology to unravel
the redox signaling networks controlling
key events such as cell differentiation
and apoptosis.
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Aptamers are RNA molecules that bind small molecules. They were originally isolated from random libraries
and then found in bacteria. In this issue ofChemistry & Biology, Vu et al. demonstrate that amotif for an aden-
osine aptamer occurs in human and bacterial genomes and binds AMP and ATP in vitro.RNA possesses both structural and func-
tional diversity. Structural diversity arises
because RNA is single stranded and can
fold back on itself, attainingmyriad imper-
fections such as bulges and loops. These
are key to structural diversity, as they form
small clefts or interact with other regions
of the RNA to make large clefts. Such
clefts can bind small molecules, giving
rise to specific molecular recognition
and ribozyme catalysis.
In theearly 1990s, groundbreakingwork
led to the identification of RNA sequences
that bind small molecules tightly and
specifically, so-called ‘‘aptamers,’’ and
established RNA enzymes with novel
functions, so-called ‘‘ribozymes’’. The
generation of these sequences relied
on a process referred to as ‘‘SELEX’’ orin vitro selection, in which random RNA
libraries, generated by transcription from
randomized DNA templates, were chal-
lenged to bind small molecules.
One of the early in vitro selection
studies, conducted by Sassanfar and
Szostak (1993), focused on the binding
of an RNA library to ATP. After eight
rounds of selection, aptamers were iso-
lated that had a fairly simple motif of an
1131 asymmetric internal loop flanked
by stems, for a total aptamer size of just
35–40 nt (Figure 1, bottom). Secondary
structure probing and structure determi-
nation revealed that this aptamer is
comprised of a simple fold-back structure
with a cleft (Dieckmann et al., 1996; Jiang
et al., 1996; Sassanfar and Szostak,
1993). This aptamer bound ATP, AMP,and adenosine with low mM Kds and
discriminated against CTP, GTP, and
UTP, as well as most ribose sugar modifi-
cations. One key question that emerged
was whether the ATP aptamer is relevant
to biology.
Over the past decade, work from
several labs has revealed that RNA
aptamers occur in nature as ‘‘ribos-
witches,’’ where they comprise an ‘‘ap-
tamer domain’’ that couples to an
‘‘expression platform’’ which effects
changes in gene expression upon ligand
binding (Grundy and Henkin, 1993; Miro-
nov et al., 2002; Winkler et al., 2002).
Riboswitches can be either ‘‘indirect,’’
binding a metabolite-sensing protein, or
‘‘direct,’’ binding a larger RNA or ametab-
olite themselves (Nilsen, 2007). Among
